Local Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2015
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 14 Oct 2014 Status changed from active, no longer recruiting to completed, as reported by the ClinicalTrials.gov record.
- 25 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.